One thing was clear at TVT 2022 in Chicago: TAVR's popularity over surgery is changing the way physicians think about patient care. 

Treating subclinical leaflet thrombosis after TAVR has been an ongoing challenge for structural heart clinicians, but recent research has gone a long way toward improving our understanding of this important topic. 

In-hospital mortality was especially high among TAVR patients presenting with hypertrophic cardiomyopathy, according to a new analysis.

Michael Mack, MD, a key pioneer in transcatheter aortic valve replacement (TAVR), explains the history of TAVR and where things are headed.

The study, published in the American Journal of Cardiology, included data from more than 900 TAVR patients. Overall morality was 22.7% among patients with AFib and 14.4% among patients without AFib.

However, the study’s authors did find associations between suboptimal TAVR procedures and adverse outcomes.

TAVR patients with gastrointestinal bleeding (GIB) were linked to longer lengths of stay and a higher risk of acute kidney injury than patients without GIB.

Researchers tracked both short- and long-term outcomes, sharing their findings in the Journal of the American Heart Association.